Q-Med: Interim Report January to September 2006.STOCKHOLM, Sweden -- Q-Med (STO:QMED): * Sales of goods during the period amounted to SEK SEK In currencies, this is the abbreviation for the Swedish Krona. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 897.8 (669.1) million, an increase of 34 percent. * Operating income amounted to SEK 259.2 (59.0) million. * Net income after tax amounted to SEK 186.7 (46.8) million. * Earnings per share for the period were SEK 1.88 (0.47). * Net income after tax for the third quarter amounted to SEK 35.3 (23.2) million. * Q-Med's first product within the area of body contouring, MACROLANE, approved for sales in Europe. * The transfer of marketing and sales of DUROLANE to Smith & Nephew was begun during the quarter. Q-Med produces, markets and sells implants for esthetic and medical use. All products are based on the company's patented technology for the production of stabilized non-animal hyaluronic acid, NASHA NASHA Non-Animal, Stabilized Hyaluronic Acid (trademark of Q-Med AB; Uppsala, Sweden) NASHA National Association for Speech and Hearing Action (Rockville, MD) [TM]. The product portfolio today contains: RESTYLANE for the filling out of lips and facial wrinkles and for facial contouring, DUROLANE, for the treatment of osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. of the hip and knee joints, DEFLUX for the treatment of vesicoureteral reflux (a malformation malformation /mal·for·ma·tion/ (-for-ma´shun) 1. a type of anomaly. 2. a morphologic defect of an organ or larger region of the body, resulting from an intrinsically abnormal developmental process. of the urinary bladder) in children and ZUIDEX, for the treatment of stress urinary incontinence stress urinary incontinence n. See stress incontinence. in women. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has approximately 580 co-workers, with approximately 390 at the company's head office and production facility in Uppsala, Sweden. The Q-Med share is listed on the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries. , Mid Cap. NASHA, DUROLANE, ZUIDEX, IMPLACER, DEFLUX, MACROLANE and all product names within the RESTYLANE family are trademarks that belong to Q-Med. This information was brought to you by Waymaker http://www.waymaker.net |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion